Dr. Nizar Tannir focuses on improving clinical trials.  In particular:

• Clinical and molecular characterization of non-clear cell RCC subtypes, particularly translocation RCC and renal medullary carcinoma
• Design and conduct of informative, biology-driven clinical trials for clear-cell and non-clear cell RCC
• Identification of circulating and tissue-based biomarkers of response to targeted agents and immune checkpoint antibodies in patients with clear-cell and non-clear cell RCC